Cargando…
The genetic landscape of programmed death ligand‐1 (PD‐L1) alterations in head and neck cancer
OBJECTIVES: Nivolumab has recently been shown in the phase III clinical trial CheckMate‐141 to have superior survival rates compared to the current standard of care chemotherapy for recurrent or metastatic platinum‐resistant head and neck squamous cell carcinoma (HNSCC). Nivolumab targets the immune...
Autores principales: | Heineman, Thomas E., Widman, Adam, Kuan, Edward C., St John, Maie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5527359/ https://www.ncbi.nlm.nih.gov/pubmed/28894827 http://dx.doi.org/10.1002/lio2.79 |
Ejemplares similares
-
Anticancer effects of thymoquinone in head and neck squamous cell carcinoma: A scoping review
por: Kwan, Kera, et al.
Publicado: (2023) -
Head & neck melanoma: A 22‐year experience of recurrence following sentinel lymph node biopsy
por: Echanique, Kristen A., et al.
Publicado: (2021) -
Head and neck cancer survivorship consensus statement from the American Head and Neck Society
por: Goyal, Neerav, et al.
Publicado: (2021) -
The promise of immunotherapy in the treatment of young adults with oral tongue cancer
por: Nasser, Hassan, et al.
Publicado: (2020) -
Contemporary management of paragangliomas of the head and neck
por: Cleere, Eoin F., et al.
Publicado: (2021)